Ligand Pharmaceuticals Inc (LGND)
EBITDA
$274.03M
TTM · Period ending: · USD
LGND EBITDA
Latest reported$274.03Mperiod ending
Latest reported$274.03Mperiod ending
LGND TTM EBITDA (-$18.40M → $274.03M)
TTM EBITDA
High-resolution chart · PNG
LGND ebitda history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | EBITDA (USD) |
|---|---|
| -38,185,000 | |
| -41,905,000 | |
| -42,367,000 | |
| -42,017,000 | |
| -42,616,000 | |
| -46,466,000 | |
| -48,935,000 | |
| -55,635,000 | |
| -59,700,000 | |
| -60,700,000 | |
| -61,900,000 | |
| -39,500,000 | |
| -32,200,000 | |
| -24,900,000 | |
| -20,900,000 | |
| -29,800,000 | |
| -24,400,000 | |
| -25,000,000 | |
| -23,200,000 | |
| -21,300,000 | |
| -25,700,000 | |
| -12,600,000 | |
| -11,000,000 | |
| -8,200,000 | |
| -5,800,000 | |
| -16,600,000 | |
| -18,400,000 |